Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.

about

The Potential Value of EGFR and P53 Immunostaining in Tumors of the Urinary Bladder.Role of DMP1 and its future in lung cancer diagnostics.The role of the cytopathologist in subtyping and epidermal growth factor receptor testing in non-small cell lung cancer: An institutional experience.

P2860

Q34736121-05D46140-751C-49B6-8F74-13ACCF28815F Q37111920-A31B77C8-045F-40EC-85D5-5819E9D46E1B Q48089422-BA26806E-FD77-489B-B849-4628D99B195D

P2860

Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.

Item

http://www.wikidata.org/entity/Q37004639

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Chasing targets for EGFR tyros ...... ng cancer: Asian perspectives.

@en

Chasing targets for EGFR tyros ...... ng cancer: Asian perspectives.

@nl

type

Item

label

Chasing targets for EGFR tyros ...... ng cancer: Asian perspectives.

@en

Chasing targets for EGFR tyros ...... ng cancer: Asian perspectives.

@nl

prefLabel

Chasing targets for EGFR tyros ...... ng cancer: Asian perspectives.

@en

Chasing targets for EGFR tyros ...... ng cancer: Asian perspectives.

@nl

P1476

Chasing targets for EGFR tyros ...... ng cancer: Asian perspectives.

@en

P2093

Sae-Won Han

http://www.w3.org/2001/XMLSchema#string

Tae-You Kim

http://www.w3.org/2001/XMLSchema#string

Yung-Jue Bang

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

P304

821-836

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737159.7.6.821

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18020911

http://www.w3.org/2001/XMLSchema#string

Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.

about

P2860

P2860

Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698